Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER RIGHT
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
1.00 · RIGHT
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.500 · CENTER RIGHT
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.054
2,788 articles tracked
7-day bias trend
LcenterR
Article Excerpt
Transaction marks one of the first clinical-stage oncology acquisitions sourced, evaluated, and executed through an AI-powered drug development platform NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) — Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced the acquisition of a majority stake in DeuterOncology, a Belgium-based company...
Read full article at Montreal Gazette ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
pending
May 6, 2026